CD19-ReTARGTPR facilitated the potent elimination of a broad range of CD19pos hematologic cancer cell lines of diverse origins (Figure 2C and Figure A1A,C) by anti-CMV CD8pos T cells, while CD19neg cell lines such as K562 and CEM remained unaffected (Figure 2C and Figure A1B). This evidence concerns the gene CD19 and hematopoietic and lymphoid cell neoplasm.